Market Movers (8-K)
See all →OID
Interpace Biosciences announced a 1-for-5 reverse stock split, effective August 27, 2026, aimed at supporting a potential Nasdaq uplisting and improving its stock's marketability.
OID
Interpace Biosciences, Inc. filed an amendment to its Form 8-K to officially disclose the adoption of its 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, following stockholder approval.
OID
Interpace Biosciences announced Q2 2026 results, with thyroid revenue up 9% year-over-year to $9.1 million, alongside improved income from continuing operations and Adjusted EBITDA.
OID
Interpace Biosciences announced first quarter 2026 financial results, reporting $9.0 million in revenue and $0.8 million in income from continuing operations, with a 12% year-over-year increase in thyroid revenue.
OID
Interpace Biosciences announced its fourth quarter and full year 2025 financial results, highlighting strong thyroid segment growth and a significant non-cash tax benefit.
Better than expected
OID
Interpace Biosciences announced preliminary 2025 thyroid testing revenue growth of 21%, initiated 2026 guidance, converted all preferred stock, and plans a Nasdaq uplisting.
Better than expected
Quarterly Earnings (10-Q)
See all →OID
Interpace Biosciences, Inc. filed its Q2 2026 Form 10-Q, detailing a revenue decrease but improved gross profit and operating income compared to the prior year, driven by a strategic shift following the loss of PancraGEN reimbursement.
Capital raise
OID
Interpace Biosciences reports a significant revenue decline and net income drop in Q3 2025, primarily due to the loss of Medicare coverage for its PancraGEN test, despite improving liquidity and reducing debt.
Worse than expected
Delay expected
Capital raise
OID
Interpace Biosciences reported a net loss of $0.64 million in Q2 2025, primarily due to the loss of Medicare reimbursement for its PancraGEN test and associated restructuring costs.
Worse than expected
Delay expected
Capital raise
OID
10-Q: Interpace Biosciences Reports Q1 2025 Results: Revenue Up, Faces PancraGEN Reimbursement Challenges
Interpace Biosciences reports increased revenue for Q1 2025 but faces challenges due to the loss of Medicare coverage for its PancraGEN test.
Worse than expected
Delay expected
Capital raise
OID
Interpace Biosciences saw a significant increase in revenue and a return to profitability in the third quarter of 2024, driven by higher test volumes.
Better than expected
Capital raise
OID
Interpace Biosciences reported a significant increase in revenue and operating income for the second quarter of 2024, driven by higher test volumes.
Better than expected
Capital raise
Annual Reports (10-K)
See all →OID
Interpace Biosciences filed an amendment to its 2025 Annual Report to include required proxy statement disclosures.
Delay expected
OID
Interpace Biosciences reports a significant net income increase in 2025 driven by a tax benefit, despite an 18% revenue decline following the discontinuation of its PancraGEN test.
Worse than expected
Capital raise
OID
Interpace Biosciences files an amendment to its 2024 Annual Report on Form 10-K to include information that was to be incorporated by reference from the company's definitive proxy statement.
OID
10-K: Interpace Biosciences Restates Financials Amid PancraGEN Uncertainty, Eyes Strategic Alternatives
Interpace Biosciences restates prior financial statements due to royalty accrual errors and navigates challenges including a potential non-coverage decision for its PancraGEN test.
Worse than expected
Capital raise
Delay expected
OID
10-K/A: Interpace Biosciences Files Amended 10-K to Include Missing Proxy Information and Certifications
Interpace Biosciences has filed an amendment to its annual report on Form 10-K to include information that was to be incorporated by reference from the company's definitive proxy statement and additional certifications.
Delay expected
OID
Interpace Biosciences achieved profitability in 2023, reporting operating income of $2.8 million, while navigating regulatory challenges and strategic shifts.
Better than expected
Capital raise
Insider Trading (Form 4)
See all →OID
Thomas W. Burnell, CEO, President & Chairman and a Director of Interpace Biosciences, Inc., reported multiple transactions in common stock on August 20, 2026.
OID
Vijay Aggarwal, a Director of Interpace Biosciences, Inc., received 69,252 shares of common stock on August 20, 2026.
OID
Fortunato R. Rocca, a Director of Interpace Biosciences, Inc., received 69,252 shares of common stock on August 20, 2026.
OID
Joseph D Keegan, a Director of Interpace Biosciences, Inc., received 69,252 shares of common stock on August 20, 2026.
OID
Stephen J Sullivan, a Director of Interpace Biosciences, Inc., received 69,252 shares of common stock on August 20, 2026.
OID
Christopher Mccarthy, CFO & COO of Interpace Biosciences, Inc., reported multiple transactions in common stock on August 20, 2026.
Proxy Statements (Def-14A)
OID
Interpace Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for August 20, 2026, to be held virtually.
OID
Interpace Biosciences, Inc. has filed a definitive proxy statement with the SEC.
OID
Interpace Biosciences will hold its annual stockholders meeting virtually on November 12, 2024, to vote on the ratification of its independent accounting firm and other business matters.
Schedule 13G - Passive Investments
OID
Douglas M. Singer has filed an Amendment No. 4 to Schedule 13G, disclosing a beneficial ownership of 4.44% of Interpace Biosciences, Inc.'s common stock.
OID
Douglas M. Singer has filed an amended Schedule 13G, reporting beneficial ownership of 5.15% of Interpace Biosciences, Inc.'s common stock as of December 31, 2024.